A case of fatal Guillain–Barre syndrome from anti-PD1 monoclonal antibody use

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 8, 2016, Pages 1869-1870

  Jacob, Aasems ^a   Unnikrishnan, Dileep C ^a   Mathew, Aju ^b   Thyagarajan, Braghadheeswar ^a   Patel, Shil ^a  

^a MONMOUTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CARBOPLATIN; IMMUNOGLOBULIN; NIVOLUMAB; PACLITAXEL; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE AREFLEXIC PARALYSIS; AGED; ARTIFICIAL VENTILATION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAPHRAGM PARALYSIS; DISEASE DURATION; DRUG RESPONSE; FATIGUE; FEMALE; GUILLAIN BARRE SYNDROME; HOSPICE CARE; HUMAN; LETTER; LIMB WEAKNESS; LOWER LIMB; MECHANICAL VENTILATOR; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSORY DYSFUNCTION; SQUAMOUS CELL LUNG CARCINOMA; TENDON REFLEX; FATALITY; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY;

AGED; ANTIBODIES, MONOCLONAL; FATAL OUTCOME; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84975128780     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-016-2191-7     Document Type: Letter

References (5)

1. Csurhes PA, Sullivan A-A, Green K, Greer JM, Pender MP, McCombe PA (2005) Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain–Barré syndrome. J Clin Neurosci 12(4):409–415
2. Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard M-A, Grob J-J (2013) A severe case of ipilimumab-induced guillain–barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36(1):77–78
3. Naidoo J, Page D, Li B et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391
4. Wilgenhof S, Neyns B (2011) Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient. Ann Oncol 22(4):991–993
5. Yuki N, Hartung H-P (2012) Guillain–Barré syndrome. N Engl J Med 366(24):2294–2304